← Back to headlines
AstraZeneca Exceeds Q1 2026 Earnings Expectations Driven by Cancer Drug Sales
AstraZeneca reported first-quarter 2026 earnings that surpassed expectations, largely attributed to strong sales of its cancer drugs. The pharmaceutical giant continues to see growth in its oncology portfolio.
29 Apr, 11:58 — 29 Apr, 11:58
Sources
Showing 1 of 1 sources
